After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...